Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer

Oncology (Williston Park). 2011 Feb;25(2):134-5, 138, 140.

Authors

Patrick G Morris¹, Clifford A Hudis, Chau T Dang

Affiliation

¹ Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

PMID: 21456384

No abstract available

Publication types

Comment

MeSH terms

Anthracyclines / administration & dosage
Anthracyclines / adverse effects
Anthracyclines / therapeutic use*
Antigens, Neoplasm / metabolism
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / metabolism
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / mortality
DNA Topoisomerases, Type II / metabolism
DNA-Binding Proteins / metabolism
Dose-Response Relationship, Drug
Female
Humans
Receptor, ErbB-2 / metabolism
Risk Factors

Substances

Anthracyclines
Antigens, Neoplasm
Antineoplastic Agents
Biomarkers, Tumor
DNA-Binding Proteins
Receptor, ErbB-2
DNA Topoisomerases, Type II